Company record
VIVORYON THERAPEUTICS N.V.
- N.V.
- NL00150002Q7
- Listed issuer
Size source: afm-register
Signals
5 on record
- EuronextOther announcement
VIVORYON THERAPEUTICS N.V.: Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update. Topic: Corporate life. Industry: 20103010 Biotechnology.
EuronextRelevance17
Watch · 80% confidence
- EuronextOther announcement
VIVORYON THERAPEUTICS N.V.: Vivoryon Therapeutics N.V. to Report Q3 2026 Financial Results on November 5, 2026. Topic: Other subject. Industry: 20103010 Biotechnology.
EuronextRelevance17
Watch · 80% confidence
- EuronextOther announcement
VIVORYON THERAPEUTICS N.V.: Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting. Topic: General meeting / Board Meeting. Industry: 20103010 Biotechnology.
EuronextRelevance17
Watch · 80% confidence
- AFM boardBoard change
M. Irsfeld, a director or supervisory board member, increased optie by 116,000 in Vivoryon Therapeutics N.V.
AFM boardRelevance39
Watch · 90% confidence
- AFM insidersInsider transaction
PlatzerInvest AG (a director of Vivoryon Therapeutics N.V.), closely associated with Platzer E.M.O., sold 226,600 gewoon aandeel (NL00150002Q7) in Vivoryon Therapeutics N.V.
AFM insidersRelevance45
Medium · 94% confidence